Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19

PHASE3TerminatedINTERVENTIONAL
Enrollment

475

Participants

Timeline

Start Date

June 15, 2020

Primary Completion Date

February 7, 2022

Study Completion Date

April 12, 2022

Conditions
COVID-19Pulmonary Embolism, Deep Vein Thrombosis
Interventions
DRUG

Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml

daily incetion s.c. for 14 days

Trial Locations (8)

4031

University Hospital Basel, Basel

8091

University Hospital Zurich, Zurich

55122

Johannes Gutenberg-Universität Mainz, Mainz

79106

Universitätsklinikum Freiburg, Freiburg im Breisgau

Unknown

Clinic of Hematology, Oncology Institute of Southern Switzerland, Bellinzona

University Hospital Bern, Bern

Hôpitaux Universitaires Genève, Geneva

Clinica Luganese Moncucco, Lugano

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Insel Gruppe AG, University Hospital Bern

OTHER

collaborator

University Hospital, Geneva

OTHER

collaborator

Centre Hospitalier Universitaire Vaudois

OTHER

collaborator

University Hospital, Basel, Switzerland

OTHER

collaborator

Oncology Institute of Southern Switzerland

OTHER

collaborator

Clinica Luganese Moncucco

OTHER

collaborator

University Hospital Freiburg

OTHER

collaborator

Mainz University

OTHER

lead

University of Zurich

OTHER